for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-FDA Grants Priority Review To Merck's Supplemental Biologics License Application For Keytruda (Pembrolizumab) For Second-Line Treatment Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

July 9 (Reuters) - Merck & Co Inc:

* FDA GRANTS PRIORITY REVIEW TO MERCK’S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR KEYTRUDA® (PEMBROLIZUMAB) FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

* MERCK & CO INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT , OR TARGET ACTION, DATE OF OCT. 30, 2020 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up